TAM
CLDX icon

TFG Asset Management’s Celldex Therapeutics CLDX Stock Holding History

TFG Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Sell
290,441
-21,875
-7% -$707K 1.7% 10
2026
Q1 		$9.91M Buy
312,316
+68,516
+28% +$1.87M 1.92% 8
2025
Q4 		$6.62M Sell
243,800
-59,800
-20% -$1.58M 1.4% 9
2025
Q3 		$7.85M Sell
303,600
-12,550
-4% -$291K 1.05% 14
2025
Q2 		$6.43M Buy
316,150
+55,150
+21% +$1.07M 1.04% 16
2025
Q1 		$4.74M Buy
261,000
+69,000
+36% +$1.54M 1.08% 15
2024
Q4 		$4.85M Buy
+192,000
New +$5.22M 1.24% 16

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TFG Asset Management's CLDX Position: Q2 2026 in Review

TFG Asset Management reduced its Celldex Therapeutics (CLDX) stake by 7% in Q2 2026, selling an estimated $707K and leaving 290,441 shares worth $10.8M. The position accounts for 1.7% of the portfolio, ranked #10.

TFG Asset Management first reported a position in CLDX in Q4 2024 and has held it in 7 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • TFG Asset Management held 290,441 shares of Celldex Therapeutics worth $10.8M as of Q2 2026.
  • TFG Asset Management sold 21,875 Celldex Therapeutics shares in Q2 2026, an estimated $707K.
  • Celldex Therapeutics made up 1.7% of TFG Asset Management's portfolio in Q2 2026, its #10 holding.
  • TFG Asset Management first reported a position in Celldex Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on TFG Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.